Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

X

Asif Suria

Everything we have picked from this writer, newest first.

62 stories Visit Asif Suria

@AsifSuria

Asif Suria on X

Yes these Celsius $CELH purchases certainly stood out when we were looking at insider buys this week. They were also buying at similar prices in May. Although those Nov 2025 purchases by the same director that was buying this week (Hal Kravitz) and by their COO were not timed well. Kravitz was previously a Coca Cola executive and has been on Celsius' board for over 10 years. We usually like to see opportunistic insider purchases by independent directors with long tenure on the board.
@AsifSuria

Asif Suria on X

Given what is happening with most housing related stocks including Floor & Decor $FND and $QXO, I would have expected to see more insider buying at these companies but that is yet to materialize. We did see the home builder D.R. Horton $DHI increase its stock buyback authorization by an additional $5 billion yesterday (nearly 13% of market cap). The last insider purchase at the company was in 2014. With mortgage rates going up, it might be too early to get into this industry but I am starting to get interested.
@AsifSuria

Asif Suria on X

Waystar $WAY putting itself up for sale just a little over two years after it went public at $21.50 is surprising to me. I used their product when I used to work in healthcare services. As most startups in healthcare services eventually realize, the money is often made on the backend RCM (revenue cycle management) side of things. Waystar is an essential link between hospitals/clinics and insurance companies helping with claims processing and rejections. Think of them like a midstream oil pipeline company connecting the independent oil & gas producers with refiners. They have hired Evercore $EVR and Barclays $BCS is also advising. The stock is down more than 30% over the last year even after accounting for the pop after this sale announcement. Feels like the baby being thrown out with the SaaS bathwater. The financials however look strong to me whether you consider improving gross margin, free cash flow that is better than net income most quarters or stable debt on the balance sheet. Revenue grew 18% year-over-year last quarters and net margin was nearly 13%. So not a GAAP unprofitable SaaS company that is giving way most of the value to employees through stock-based compensation. I'll have to dig into competitive dynamics and understand the business better. What am I missing?
@AsifSuria

Asif Suria on X

Came across another Flip Flopper Special last night: The organ transplant company TransMedics Group $TMDX is up more than 4% today in a down market after Director David Weill waited a few days beyond the six month period to buy stock at $81.63. The six month part was important as he would have had to give back profits to the company if he had purchased within six months of his prior sale. I looked at his history of purchases and sales of TMDX and he has gotten it right multiple times over the last six years. Dr. Weill, has been on the board of TransMedics since 2019 as an independent director and he was previously the Director of the Lung and Heart-Lung Transplant Program at Stanford University Medical Center. Much like the CEO of $TDW that was mentioned in my tweet below from December 2024, David Weill's last sale was on March 4, 2026 at an average price of $146.82. The insider purchase by the CEO of Tidewater, prompted us to write about the company for our January 2025 Special Situations newsletter and we added the stock to the model portfolio and I also hold it in my personal portfolio. I expect we will pretty much do the same thing with TransMedics for our next Insider Weekends article or our October 2026 newsletter.
@AsifSuria

Asif Suria on X

It takes courage to go against the current looking for opportunities that the market will not reward in the short-term. Times of turmoil is when we pay special attention to insiders and they led us to energy stock in mid-2020, regional banks in H1 2023, biotech companies in early 2025 and more recently SaaS stocks. While I don't have a position in $NOW, we did start positions in $CRM, $NAVN (partially exited) and more. Here is some of what I wrote about that decision to double down on SaaS in our July 2026 newsletter:
@AsifSuria

Asif Suria on X

The empire building at the Honeywell spinoff Solstice $SOLS came to an abrupt stop even before it started. In a highly unusual move, Solstice and Element Solutions $ESI decided to call off their merger. What makes this move particularly unusual is that neither party will have to pay a termination fee. In the words of Solstice Chairman Rajeev Gautam: "Following conversations with our shareholders and discussions between the parties, both Boards unanimously believe that it is in the best interests of our respective shareholders, employees and customers to terminate the merger agreement" The spread on this deal was as high as 9.13% at the end of last month. Solstice was up after hours yesterday on this news and is likely to post gains during the regular trading session today not just because shareholders are relieved this merger is over. Considering this was a cash plus stock deal with a majority of the payout in stock of Solstice, any arbs that want to unwind this trade will now have to buy shares of Solstice to close out the short leg of their merger arbitrage trade. This is one of the reasons I avoid "all stock" or "cash plus stock deals". You could end up getting hit on both sides of the trade when the stock of the target drops and the stock of the acquiring company spikes on deal termination. In this case, the premium paid for $ESI was about 15% and instead of the stock going up when the deal was announced, it actually fell due to the big drop in Solstice's stock. So we might not see a large drop in Element Solutions and it is possible it might even go up.